AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
We have 5 of 99 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current evidence gaps, and the need for prospective studies.
Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.
While most studies of Alzheimer's disease (AD) examine cross‐sectional relationships among biomarkers, longitudinal relationships are also highly relevant.
Whether these proteins, alone or combined with plasma phosphorylated tau 217 (p‐tau217), predict progression from cognitively unimpaired to symptomatic AD is evaluated.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.